Reiko Kaji

1.7k total citations
44 papers, 1.2k citations indexed

About

Reiko Kaji is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Reiko Kaji has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Reiko Kaji's work include Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (13 papers). Reiko Kaji is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (13 papers). Reiko Kaji collaborates with scholars based in Japan, United States and Italy. Reiko Kaji's co-authors include Akito Hata, Shiro Fujita, Nobuyuki Katakami, Yukihiro Imai, Keisuke Tomii, Katsuhiro Masago, Hiroshige Yoshioka, Tadashi Ishida, Akihiro Nishiyama and Nobuyuki Katakami and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Reiko Kaji

43 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reiko Kaji Japan 20 1.0k 793 249 236 65 44 1.2k
Tejas Patil United States 16 624 0.6× 544 0.7× 161 0.6× 228 1.0× 66 1.0× 67 836
Pil Gyu Hwang South Korea 9 992 1.0× 858 1.1× 186 0.7× 341 1.4× 46 0.7× 11 1.1k
Pierpaolo Camplese Italy 8 815 0.8× 627 0.8× 229 0.9× 273 1.2× 85 1.3× 17 988
Jaromı́r Roubec Czechia 9 1.3k 1.3× 1.3k 1.6× 170 0.7× 574 2.4× 55 0.8× 23 1.7k
Xinmin Yu China 18 704 0.7× 746 0.9× 217 0.9× 193 0.8× 112 1.7× 48 1.1k
Rocco Sacco Italy 11 877 0.9× 658 0.8× 255 1.0× 392 1.7× 103 1.6× 12 1.2k
J.M.G.H. van Riel Netherlands 14 415 0.4× 720 0.9× 382 1.5× 199 0.8× 98 1.5× 25 989
Paola Bordi Italy 17 798 0.8× 800 1.0× 353 1.4× 413 1.8× 54 0.8× 51 1.2k
Yasir Y. Elamin United States 16 518 0.5× 595 0.8× 164 0.7× 284 1.2× 127 2.0× 68 968

Countries citing papers authored by Reiko Kaji

Since Specialization
Citations

This map shows the geographic impact of Reiko Kaji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reiko Kaji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reiko Kaji more than expected).

Fields of papers citing papers by Reiko Kaji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reiko Kaji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reiko Kaji. The network helps show where Reiko Kaji may publish in the future.

Co-authorship network of co-authors of Reiko Kaji

This figure shows the co-authorship network connecting the top 25 collaborators of Reiko Kaji. A scholar is included among the top collaborators of Reiko Kaji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reiko Kaji. Reiko Kaji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Hida, Toyoaki, Reiko Kaji, Miyako Satouchi, et al.. (2018). Atezolizumab in Japanese Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. Clinical Lung Cancer. 19(4). e405–e415. 48 indexed citations
4.
Sakanoue, Ichiro, Hiroshi Hamakawa, Reiko Kaji, et al.. (2018). Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib. Journal of Thoracic Disease. 10(3). E170–E174. 3 indexed citations
5.
Hata, Akito, Nobuyuki Katakami, Shigeki Nanjo, et al.. (2017). Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. In Vivo. 31(3). 475–479. 7 indexed citations
6.
Nanjo, Shigeki, Akito Hata, Chiyuki Okuda, et al.. (2017). Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. British Journal of Cancer. 118(1). 32–37. 69 indexed citations
7.
Tanaka, Kosuke, Toyoaki Hida, Yuko Oya, et al.. (2015). EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma. Journal of Thoracic Oncology. 10(12). 1720–1725. 54 indexed citations
8.
Otsuka, Kyoko, Akito Hata, Jumpei Takeshita, et al.. (2015). EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 76(4). 835–841. 39 indexed citations
9.
Fujita, Shiro, Katsuhiro Masago, Jumpei Takeshita, et al.. (2015). Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer. PLoS ONE. 10(6). e0130219–e0130219. 6 indexed citations
10.
Masago, Katsuhiro, Shiro Fujita, Miho Muraki, et al.. (2015). Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer. 15(1). 908–908. 27 indexed citations
11.
12.
Kaneda, Toshihiko, Akito Hata, Hiromi Tomioka, et al.. (2014). Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Lung Cancer. 86(2). 213–218. 27 indexed citations
13.
Takeshita, Jumpei, Katsuhiro Masago, Shiro Fujita, et al.. (2014). Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients. Molecular and Clinical Oncology. 2(3). 454–460. 1 indexed citations
14.
Hata, Akito, Nobuyuki Katakami, Hiroshige Yoshioka, et al.. (2013). Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor. Cancer. 119(24). 4325–4332. 153 indexed citations
15.
Tanaka, Kosuke, Akito Hata, Reiko Kaji, et al.. (2013). Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation. Journal of Thoracic Oncology. 8(7). 892–898. 41 indexed citations
16.
Hata, Akito, Nobuyuki Katakami, Kei Kunimasa, et al.. (2011). Erlotinib for Pretreated Squamous Cell Carcinoma of the Lung in Japanese Patients. Japanese Journal of Clinical Oncology. 41(12). 1366–1372. 14 indexed citations
17.
Hata, Akito, Nobuyuki Katakami, Hiroshige Yoshioka, et al.. (2011). Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection. Lung Cancer. 74(2). 268–273. 53 indexed citations
18.
Hata, Akito, Nobuyuki Katakami, Shiro Fujita, et al.. (2010). Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer. Lung Cancer. 72(2). 224–228. 5 indexed citations
19.
Hata, Akito, Hiroshige Yoshioka, Shiro Fujita, et al.. (2010). Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(10). 1524–1528. 71 indexed citations
20.
Hata, Akito, et al.. (2009). Three Cases of Leptomeningeal Carcinomatosis from Lung Adenocarcinoma Responding to EGFR TKIs. Haigan. 49(4). 461–466. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tejas Patil Breakdown of academic impact, for papers by Pil Gyu Hwang Breakdown of academic impact, for papers by Pierpaolo Camplese Breakdown of academic impact, for papers by Jaromı́r Roubec Breakdown of academic impact, for papers by Xinmin Yu Breakdown of academic impact, for papers by Rocco Sacco Breakdown of academic impact, for papers by J.M.G.H. van Riel Breakdown of academic impact, for papers by Paola Bordi Breakdown of academic impact, for papers by Yasir Y. Elamin
Rankless by CCL
2026